Clinical Trial Search

Primary: Number of Participants With a Treatment Response — 38; 17 Participants

Primary: Percentage of Subjects With Seropositivity Rates for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity) — 16.7; 83.3; 16.7; 66.7 % of subjects

Primary: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) — 25.3; 3.9 percentage of participants — p=<0.001

Primary: Time to Treatment Failure — 4.5; 6.9 Months

Primary: Number of Subjects With Vaccine Response for Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (rSBA-MenA…

Primary: Change From Baseline in PANSS(Positive and Negative Syndrome Scale) Total Score at Week 8 — -30.59; -33.56; -33.71; -36.31 score on a scale — p=<0.05

Primary: Safety - Most Frequently Reported Adverse Events and Grade — 5; 9; 0; 4 adverse events

Primary: Safety - Most Frequently Reported Adverse Events and Grade — 3; 10; 0; 2 Number of adverse events

Primary: Number of Participants With Exhaled Carbon Monoxide Confirmed Abstinence — 53; 65 participants

Primary: Number of Participants With Unnecessary Invasive Coronary Angiography — 36; 34; 69 Participants

Primary: Success Rate of Placement of a Thoracic Epidural — 41; 45 Participants

Primary: Emotion Recognition Questionnaire — 18.67; 17.00; 17.00; 16.40 score on a scale

Primary: Area Over the Curve and <60 mg/dl (CGM) Measured in mg/dl *Min — 1066.30; 2004.80 mg/dl *minute

Primary: Number of Participants With Any Positive Inhibitor Development — 0; 0; 0 Participants

Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants